Non-invasive prenatal testing (NIPT) analyzes cell-free DNA circulating in maternal blood to screen for certain chromosomal conditions in a developing fetus. A sample report typically includes information about the fetal sex and assesses the risk for common trisomies (such as Down syndrome, Edwards syndrome, and Patau syndrome). Some tests may also screen for sex chromosome aneuploidies and certain microdeletions. Illustrative reports often demonstrate how these risks are presented, usually as low or high, alongside explanations of the methodology and limitations of the screening.
Offering a screening method with high sensitivity and specificity for common chromosomal abnormalities, NIPT represents a significant advancement in prenatal care. It provides expectant parents with information early in pregnancy, allowing them to make informed decisions about further diagnostic testing and pregnancy management. This approach has largely replaced more invasive procedures, like chorionic villus sampling and amniocentesis, as the first-line screening test in many cases, reducing the risk of procedure-related pregnancy complications. The development and refinement of this technology have greatly improved access to safe and reliable aneuploidy screening.
